Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527544 | 0.92 | KMT2A (0.71) | KMT2APKMMAPTHGFACALOX5 | |
| SCHEMBL9333093 | 0.88 | KMT2A (0.66) | KMT2APKMMAPTHGFACALOX5 | |
| P-Nitrophenol SCHEMBL7158777 | 0.87 | KMT2A (0.64) | KMT2APKMMAPTHGFACALOX5 | |
| SCHEMBL5973956 | 0.86 | ALOX5 (0.73) | KMT2APKMMAPTHGFACALOX5 | |
| SCHEMBL12649366 | 0.85 | ALOX5 (0.68) | KMT2APKMMAPTHGFACALOX5 | |
| SCHEMBL4951809 | 0.84 | KMT2A (0.84) | KMT2APKMMAPTHGFACALOX5 | |
| SCHEMBL18434657 | 0.84 | KMT2A (0.84) | KMT2APKMMAPTHGFACALOX5 | |
| SCHEMBL542043 | 0.84 | KMT2A (0.84) | KMT2APKMMAPTHGFACALOX5 | |
| SCHEMBL10636579 | 0.84 | KMT2A (0.84) | KMT2APKMMAPTHGFACALOX5 | |
| SCHEMBL6032592 | 0.84 | KMT2A (0.68) | KMT2APKMMAPTHGFACALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838006-B2 | Viral vaccine composition, process and methods of use | IMMUNITOR USA INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090226489-A1 | VIRAL VACCINE COMPOSITION, PROCESS AND METHODS OF USE | IMMUNITOR USA INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20030092145-A1 | Viral vaccine composition, process, and methods of use | IMMUNITOR USA INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2001054717-A1 | VACCINE COMPOSITION, PROCESS AND METHODS | JIRA VIC (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6020315-A | Preparation having increased in vivo tolerability | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-01 | — | — | US | disclosed |